The Puerto Rico Court of Appeals recently upheld the award of a contract to PharmPix Corporation for pharmacy benefit management services, rejecting a challenge from the Cooperativa de Farmacias Puertorriqueñas (Coopharma). The ruling, issued on August 31, 2026, is significant as it reinforces the discretion of government agencies in awarding contracts and highlights the importance of transparency in the bidding process.
The case, identified by docket number TA2026AP00718, arose from a dispute over a Request for Proposal (RFP) issued by the Corporación del Fondo del Seguro del Estado (CFSE). The CFSE sought proposals for managing pharmacy benefits, including the distribution of medications and integration with its electronic billing system. Coopharma contested the award, arguing that PharmPix did not meet essential requirements for the contract.
In March 2026, the CFSE published the RFP, inviting bids from interested parties. Four bidders attended a mandatory informational meeting, including Coopharma and PharmPix. After submitting their proposals, the CFSE formed a committee to evaluate the submissions. The committee ultimately recommended PharmPix, citing its favorable economic proposal and superior technological capabilities.
Coopharma challenged the award, claiming that PharmPix was not ready to provide services by the required start date of July 1, 2026. Coopharma also alleged that it was denied access to the committee's evaluation report and PharmPix's proposal, which hindered its ability to contest the decision effectively. After the CFSE's resolution in favor of PharmPix, Coopharma sought a review from the Junta Revisora de Subastas, but the review was deemed rejected due to inaction.
The court ruled that the CFSE acted within its rights in awarding the contract to PharmPix. The opinion stated, "The evidence does not support Coopharma's claim that PharmPix was disqualified for not being ready to provide services on the specified date." The court emphasized that the CFSE's evaluation process was thorough and based on substantial evidence.
In its decision, the court noted that the CFSE provided a detailed resolution that outlined the evaluation process and the criteria used to select PharmPix. The judges found that Coopharma's claims lacked merit, particularly regarding the alleged failure of PharmPix to meet the service commencement date, which was not explicitly stated in the RFP.
The ruling also addressed Coopharma's concerns about transparency in the bidding process. The court clarified that while access to some documents is necessary, the CFSE was not obligated to disclose internal evaluations and recommendations during the adjudication process. The judges concluded that the CFSE's resolution contained sufficient information to support its decision.
This ruling has important implications for future government contract awards in Puerto Rico. It reinforces the principle that agencies have significant discretion in evaluating proposals and awarding contracts, as long as their decisions are supported by substantial evidence. The decision also underscores the importance of clear communication and documentation throughout the bidding process.
Looking ahead, Coopharma may seek to appeal the ruling, although the court's decision sets a strong precedent in favor of the CFSE's discretion in contract awards. The case highlights the ongoing challenges faced by bidders in navigating the complexities of government procurement processes.